论文部分内容阅读
目的:观察双歧杆菌三联活菌治疗婴儿胆汁淤积性肝病(ICH)患儿的临床疗效。方法:将临床诊断为ICH的104例患儿按随机数字表法分为治疗组及对照组。两组均给予必要的抗感染、抗病毒及保肝利胆等常规综合治疗,治疗组在此基础上加用双歧杆菌三联活菌,0.5 g/次,每日3次。两组疗程均为2周。对两组临床疗效及肝功能相关指标进行比较分析。结果:治疗组总有效率为84.62%,对照组总有效率为67.31%,两组总有效率的比较,差异有统计学意义(P<0.05)。与对照组相比,治疗组治疗后总胆红素(Tbil)、直接胆红素(Dbil)、总胆汁酸(TBA)显著降低,差异有统计学意义(P<0.01)。而谷丙转氨酶(ALT)、白蛋白(ALB)虽有不同程度改善,但差异无统计学意义(P>0.05)。结论:双歧杆菌三联活菌能调节肠道菌群失调,有助于ICH患儿临床症状体征的改善及肝功能的恢复。
Objective: To observe the clinical efficacy of Bifidobacterium triple viable bacteria in the treatment of infantile cholestatic liver disease (ICH). Methods: 104 cases of clinically diagnosed ICH were randomly divided into treatment group and control group. The two groups were given the necessary anti-infective, antiviral and hepatoprotective gallbladder and other conventional comprehensive treatment, the treatment group on this basis, add Bifidobacterium triple viable bacteria, 0.5 g / times, 3 times a day. Two groups of treatment are 2 weeks. The two groups of clinical efficacy and liver function-related indicators for comparative analysis. Results: The total effective rate was 84.62% in the treatment group and 67.31% in the control group. There was significant difference between the two groups in the total effective rate (P <0.05). Compared with the control group, the total bilirubin (Tbil), direct bilirubin (Dbil) and total bile acid (TBA) in the treatment group were significantly decreased after treatment (P <0.01). However, ALT and ALB were improved to some extent, but there was no significant difference (P> 0.05). Conclusion: Bifidobacterium triple live bacteria can regulate intestinal flora, contribute to the improvement of clinical symptoms and signs of ICH children and liver function recovery.